Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Medulloblastoma: early-phase trial registry
13 of 30 indexed Medulloblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 13 currently recruiting · #519 of 28,707 conditions by registered trial count
Medulloblastoma: 30 US clinical trials tracked, 13 recruiting.
Medulloblastoma is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 6 of these trials.
Enrollment posture brief
Registry condition medulloblastoma
OPEN 13 | RECR 43% | LATE 4 | EARLY 23 | RANK #519 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Bronchopulmonary Dysplasia (43% recruiting · 30 trials)
Medulloblastoma lists 13 open slots (43% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Medulloblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Medulloblastoma is recruiting above its size-band peers.
13 of 30 indexed trials (43.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Medulloblastoma research.
St. Jude Children's Research Hospital accounts for 6 of 30 trials (20%). 20 distinct sponsors appear on at least one study for this condition label.
-
Typical Medulloblastoma enrolment sits around 74 participants.
Median target enrolment is 74 among the 30 trials that report a genuine target (sentinel values excluded). 17 of those (56.7%) plan for fewer than 100 participants.
-
Medulloblastoma research is mostly interventional.
29 interventional and 1 observational studies make up this index (96.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Weill Medical College of Cornell University
NCT04081701
CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
St. Jude Children's Research Hospital
NCT07085325
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Cancer Institute (NCI)
NCT06161519
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
St. Jude Children's Research Hospital
NCT05535166
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Giselle Sholler
NCT04696029
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
University of California, San Francisco
NCT05057702
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
NCT05278208
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
St. Jude Children's Research Hospital
NCT05835687
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Theodore S. Johnson
NCT05106296
Digoxin Medulloblastoma Study
H. Lee Moffitt Cancer Center and Research Institute
NCT06701812
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies
NCT04337177
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Emory University
NCT06624371
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Stanford University
NCT07087002
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
St. Jude Children's Research Hospital
NCT01878617
Methionine PET/CT Studies In Patients With Cancer
St. Jude Children's Research Hospital
NCT00840047
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
Children's Oncology Group
NCT00392327
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
Parth Patel
NCT02875314
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Theodore S. Johnson
NCT04049669
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
NCT03709680
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Children's Oncology Group
NCT02724579
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
NCT04978727
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
Pediatric Brain Tumor Consortium
NCT03389802
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
St. Jude Children's Research Hospital
NCT05128903
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Seattle Children's Hospital
NCT03500991
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
City of Hope Medical Center
NCT04661384
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Children's Oncology Group
NCT00085735
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Sue O'Dorisio
NCT02441062
Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma
Massachusetts General Hospital
NCT01063114
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
Novartis Pharmaceuticals
NCT01708174
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
Emory University
NCT01331135
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 11 |
| Phase 3 | 2 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Medulloblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Medulloblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Medulloblastoma page
30 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Medulloblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- St. Jude Children's Research Hospital sponsors the most Medulloblastoma trials on record, review their full trial history before evaluating a specific study. See St. Jude Children's Research Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Medulloblastoma condition card totals 30 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.